Lixte Biotechnology (LIXT) Competitors

$5.88 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$5.84 -0.04 (-0.77%)

As of 05/22/2026 05:34 PM Eastern

LIXT vs. UNCY, MGNX, NKTX, CNTX, and CRBP

Should you buy Lixte Biotechnology stock or one of its competitors? MarketBeat compares Lixte Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lixte Biotechnology include Unicycive Therapeutics (UNCY), MacroGenics (MGNX), Nkarta (NKTX), Context Therapeutics (CNTX), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical products" industry.

How does Lixte Biotechnology compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Lixte Biotechnology has lower revenue, but higher earnings than Unicycive Therapeutics. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	317.26	-$26.56M	-$2.21	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

Unicycive Therapeutics has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Unicycive Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 197.03%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Unicycive Therapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 10.7% of Unicycive Therapeutics shares are held by insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Unicycive Therapeutics' return on equity of -134.69% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Lixte Biotechnology	N/A	-134.91%	-95.61%

In the previous week, Unicycive Therapeutics had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 4 mentions for Unicycive Therapeutics and 1 mentions for Lixte Biotechnology. Unicycive Therapeutics' average media sentiment score of 1.16 beat Lixte Biotechnology's score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Unicycive Therapeutics beats Lixte Biotechnology on 12 of the 14 factors compared between the two stocks.

How does Lixte Biotechnology compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

MacroGenics presently has a consensus target price of $5.50, indicating a potential upside of 21.41%. Given MacroGenics' stronger consensus rating and higher possible upside, research analysts clearly believe MacroGenics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lixte Biotechnology has lower revenue, but higher earnings than MacroGenics. Lixte Biotechnology is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.93	-$74.62M	-$1.10	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

In the previous week, MacroGenics had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 3 mentions for MacroGenics and 1 mentions for Lixte Biotechnology. MacroGenics' average media sentiment score of 0.28 beat Lixte Biotechnology's score of 0.00 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lixte Biotechnology has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Lixte Biotechnology's return on equity of -134.91% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Lixte Biotechnology	N/A	-134.91%	-95.61%

MacroGenics has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

MacroGenics beats Lixte Biotechnology on 12 of the 15 factors compared between the two stocks.

How does Lixte Biotechnology compare to Nkarta?

Lixte Biotechnology (NASDAQ:LIXT) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

In the previous week, Lixte Biotechnology and Lixte Biotechnology both had 1 articles in the media. Nkarta's average media sentiment score of 2.00 beat Lixte Biotechnology's score of 0.00 indicating that Nkarta is being referred to more favorably in the news media.

Company	Overall Sentiment
Lixte Biotechnology	Neutral
Nkarta	Very Positive

Nkarta has a consensus price target of $10.75, suggesting a potential upside of 254.79%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Nkarta's return on equity of -30.90% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Nkarta	N/A	-30.90%	-24.20%

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by insiders. Comparatively, 8.4% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lixte Biotechnology has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Summary

Nkarta beats Lixte Biotechnology on 9 of the 13 factors compared between the two stocks.

How does Lixte Biotechnology compare to Context Therapeutics?

Lixte Biotechnology (NASDAQ:LIXT) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Context Therapeutics is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A

Context Therapeutics has a consensus price target of $6.60, suggesting a potential upside of 153.85%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Lixte Biotechnology and Lixte Biotechnology both had 1 articles in the media. Context Therapeutics' average media sentiment score of 0.66 beat Lixte Biotechnology's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lixte Biotechnology has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Context Therapeutics' return on equity of -59.95% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Context Therapeutics	N/A	-59.95%	-54.78%

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Context Therapeutics beats Lixte Biotechnology on 10 of the 13 factors compared between the two stocks.

How does Lixte Biotechnology compare to Corbus Pharmaceuticals?

Lixte Biotechnology (NASDAQ:LIXT) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 4 mentions for Corbus Pharmaceuticals and 1 mentions for Lixte Biotechnology. Corbus Pharmaceuticals' average media sentiment score of 0.27 beat Lixte Biotechnology's score of 0.00 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Lixte Biotechnology has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.68, meaning that its stock price is 168% more volatile than the broader market.

Corbus Pharmaceuticals' return on equity of -70.89% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Corbus Pharmaceuticals has a consensus target price of $42.89, indicating a potential upside of 277.88%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Corbus Pharmaceuticals beats Lixte Biotechnology on 11 of the 14 factors compared between the two stocks.

Get Lixte Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIXT vs. The Competition

Export

Metric	Lixte Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$72.81M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-5.20	18.74	21.22	25.65
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	7.95	7.09	10.37	7.14
Net Income	-$6.01M	$24.45M	$3.57B	$335.98M
7 Day Performance	11.57%	6.38%	6.40%	4.15%
1 Month Performance	58.49%	2.43%	3.52%	2.54%
1 Year Performance	345.45%	62.98%	34.02%	35.05%

Lixte Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIXT Lixte Biotechnology	0.5017 of 5 stars	$5.88 flat	N/A	+345.5%	$72.81M	N/A	N/A	4
UNCY Unicycive Therapeutics	3.3437 of 5 stars	$8.51 +4.2%	$24.00 +182.0%	+46.1%	$227.22M	N/A	N/A	9	Positive News Gap Down
MGNX MacroGenics	2.2094 of 5 stars	$3.45 -2.0%	$5.40 +56.5%	+200.0%	$219.28M	$149.50M	N/A	430
NKTX Nkarta	3.9956 of 5 stars	$3.06 -6.7%	$11.33 +270.4%	+73.1%	$218.15M	N/A	N/A	140	Gap Down
CNTX Context Therapeutics	3.1434 of 5 stars	$2.36 -4.8%	$6.60 +179.7%	+275.2%	$216.83M	N/A	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIXT) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lixte Biotechnology (LIXT) Competitors

LIXT vs. UNCY, MGNX, NKTX, CNTX, and CRBP

How does Lixte Biotechnology compare to Unicycive Therapeutics?

Summary

How does Lixte Biotechnology compare to MacroGenics?

Summary

How does Lixte Biotechnology compare to Nkarta?

Summary

How does Lixte Biotechnology compare to Context Therapeutics?

Summary

How does Lixte Biotechnology compare to Corbus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lixte Biotechnology (LIXT) Competitors

LIXT vs. UNCY, MGNX, NKTX, CNTX, and CRBP

How does Lixte Biotechnology compare to Unicycive Therapeutics?

Which has preferable valuation & earnings, UNCY or LIXT?

Which has more volatility & risk, UNCY or LIXT?

Do analysts prefer UNCY or LIXT?

Do insiders and institutionals hold more shares of UNCY or LIXT?

Is UNCY or LIXT more profitable?

Does the media favor UNCY or LIXT?

Summary

How does Lixte Biotechnology compare to MacroGenics?

Do analysts prefer MGNX or LIXT?

Which has stronger valuation and earnings, MGNX or LIXT?

Does the media favor MGNX or LIXT?

Is MGNX or LIXT more profitable?

Which has more risk and volatility, MGNX or LIXT?

Do insiders & institutionals hold more shares of MGNX or LIXT?

Summary

How does Lixte Biotechnology compare to Nkarta?

Does the media favor LIXT or NKTX?

Do analysts rate LIXT or NKTX?

Is LIXT or NKTX more profitable?

Do insiders & institutionals have more ownership in LIXT or NKTX?

Which has more volatility & risk, LIXT or NKTX?

Which has preferable earnings & valuation, LIXT or NKTX?

Summary

How does Lixte Biotechnology compare to Context Therapeutics?

Which has preferable earnings and valuation, LIXT or CNTX?

Do analysts prefer LIXT or CNTX?

Does the media favor LIXT or CNTX?

Which has more volatility & risk, LIXT or CNTX?

Is LIXT or CNTX more profitable?

Do insiders and institutionals have more ownership in LIXT or CNTX?

Summary

How does Lixte Biotechnology compare to Corbus Pharmaceuticals?

Which has stronger earnings and valuation, LIXT or CRBP?

Do institutionals and insiders believe in LIXT or CRBP?

Does the media favor LIXT or CRBP?

Which has more risk and volatility, LIXT or CRBP?

Is LIXT or CRBP more profitable?

Do analysts recommend LIXT or CRBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools